Krystal Biotech (NASDAQ:KRYS) Insider Suma Krishnan Sells 25,000 Shares of Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the completion of the transaction, the insider owned 1,378,155 shares in the company, valued at approximately $424,623,337.05. The trade was a 1.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Krystal Biotech Trading Down 2.2%

Shares of NASDAQ KRYS opened at $301.00 on Friday. The firm’s 50-day moving average price is $282.39 and its 200-day moving average price is $264.19. Krystal Biotech, Inc. has a 1-year low of $127.99 and a 1-year high of $319.48. The firm has a market capitalization of $8.87 billion, a P/E ratio of 40.24 and a beta of 0.53.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, May 4th. The company reported $1.83 earnings per share for the quarter, beating the consensus estimate of $1.45 by $0.38. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. The firm had revenue of $116.36 million for the quarter, compared to analyst estimates of $112.11 million. Equities research analysts forecast that Krystal Biotech, Inc. will post 7.83 EPS for the current year.

Institutional Investors Weigh In On Krystal Biotech

Several hedge funds and other institutional investors have recently made changes to their positions in KRYS. Soleus Capital Management L.P. increased its position in shares of Krystal Biotech by 108.9% during the second quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock worth $126,870,000 after acquiring an additional 481,200 shares in the last quarter. Norges Bank bought a new stake in shares of Krystal Biotech during the fourth quarter worth about $70,159,000. William Blair Investment Management LLC grew its position in Krystal Biotech by 152.1% in the 4th quarter. William Blair Investment Management LLC now owns 376,340 shares of the company’s stock worth $92,783,000 after purchasing an additional 227,038 shares in the last quarter. Janus Henderson Group PLC grew its position in Krystal Biotech by 2,078.9% in the 4th quarter. Janus Henderson Group PLC now owns 219,440 shares of the company’s stock worth $54,147,000 after purchasing an additional 209,369 shares in the last quarter. Finally, UBS Group AG grew its position in Krystal Biotech by 970.8% in the 4th quarter. UBS Group AG now owns 159,595 shares of the company’s stock worth $39,347,000 after purchasing an additional 177,922 shares in the last quarter. 86.29% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Evercore reiterated an “outperform” rating and set a $300.00 price objective on shares of Krystal Biotech in a report on Tuesday, May 5th. Wolfe Research began coverage on shares of Krystal Biotech in a research report on Friday, March 27th. They set a “peer perform” rating for the company. Weiss Ratings raised shares of Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, April 9th. Jefferies Financial Group boosted their target price on shares of Krystal Biotech from $310.00 to $371.00 and gave the stock a “buy” rating in a research report on Tuesday, February 17th. Finally, Citigroup boosted their target price on shares of Krystal Biotech from $371.00 to $378.00 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Ten research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $324.11.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.